NEW YORK (TheStreet) -- CHANGE IN RATINGS
American Airlines AAL was initiated at UBS with a neutral rating. $29 price target. The company trades at a discount on earnings, but has weak free cash flow generation with capital expenditure and merger integration, said UBS.
Abbvie (ABBV) was downgraded to equal-weight from overweight at Morgan Stanley. $57 price target. This is a valuation call, Morgan Stanley said.
Cubic Corp (CUB) was upgraded to overweight from neutral at JP Morgan. $57 price target. The company was upgraded ahead of a transportation ramp up, JP Morgan said.
[Read: Fed Policy Creates Wall Street Shenanigans]
CVS Caremark (CVS) price target was raised to $82 with an overweight rating at JP Morgan. There is additional upside after the analyst day conference, JP Morgan said.
Delta Air Lines (DAL) was initiated with a buy rating at UBS. $39 price target. Delta's flexible operating model has lower fixed costs, better cash generation and higher return on invested capital than peers, UBS said.
Rocket Fuel (FUEL) upgraded from buy to strong buy by Needham. The stock has pulled back 30%, but industry checks remain positive, Needham said.
Gamestop (GME) was started with a hold rating at Benchmark. $38.55 price target. The company is leveraged to new game consoles but could face increased competition in the future, said Benchmark.
Liquidity Services (LQDT) was downgraded to a hold rating at TheStreet Ratings.
Omnicom (OMC) was upgraded to buy at Goldman Sachs. $88 price target. Merger synergies should drive growth over the next several quarters, said Goldman.
Puma Biotechnology (PBYI) was downgraded to hold from buy by Stifel Nicolaus said. This is a valuation call, Stifel said.
[Read: Caterpillar Will Plow Ahead, Despite Fraud Setback]
Polo Ralph Lauren (RL) was initiated with a buy rating at Janney Montgomery said. $200 price target. The company can continue to expand its brand and grow across the globe, Janney said.
SeaChange International (SEAC) was downgraded to a hold rating at TheStreet Ratings.
Sirius XM (SIRI) was upgraded to buy from hold at Wunderlich. $4.20 price target. The stock is attractive, following a 17% selloff, Wunderlich said..
Semtech (SMTC) was downgraded to perform from outperform at Oppenheimer. Estimates were also cut, given the company's new guidance, Oppenheimer said.
Symantec (SYMC) was initiated with a market perform rating by BMO Capital. $24 price target. The company lacks near-term catalysts, said BMO.
Stock Comments / EPS Changes
Anadarko Petroleum (APC) price target was decreased at UBS. The company lowered its numbers, UBS said, driven by potential Tronox liability. $95 price target and buy rating.
Celgene (CELG) estimates, price target were increased at Bank of America/Merrill Lynch. Celgene's estimates were raised through 2015, BofA/Merrill said. Expect higher Revlimid and Pomalyst sales. Buy rating and new $196 price target.
Ford Motor Company (F) price target, estimates were decreased at Jefferies. Ford had lower numbers, Jefferies said. A heavy launch schedule led company to lower North American volumes and margins. $18 price target and buy rating.
Ford (F) price target, estimates were decreased at Sterne Agee. Ford estimates were reduced through 2015, Sterne Agee said. The company lowered its guidance. Buy rating and new $19 price target.
FedEx (FDX) target price, estimates were raised at Credit Suisse. Shares of FDX are now seen reaching $139, according to Credit Suisse. Estimates also increased, as the company is buying back more stock. Neutral rating.
Fiesta Restaurant Group (FRGI) price target, earnings per share increased at Jefferies. Fiesta lifted their numbers across the board; this is a large growth story with accretive transactions, Jefferies said. $57 price target and buy rating.
[Read: Target Reports 40 Million Credit, Debit Cards May Have Been Hacked]
General Mills (GIS) price target, estimates were reduced at BMO Capital. Shares of General Mills are now seen reaching $53, according to BMO. Estimates were also cut, as the company is seeing lower domestic retail demand. Outperform rating.
Oracle (ORCL) price target, estimates were increased at Pacific Crest. Shares of Oracle are now seen reaching $40, according to Pacific Crest. Estimates were also upped, as the company is seeing higher sales across the board. Outperform rating.
Puma Biotechnology (PBYI) price target was increased at UBS. There is greater confidence in Neratinib's peak potential. $125 price target and buy rating.